To include your compound in the COVID-19 Resource Center, submit it here.

InVivo Therapeutics neurology news

InVivo will reduce headcount by 14 (28%) to 36 and will discontinue development of its hydrogel drug delivery program,

Read the full 190 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE